Neurological Disorder Drugs Market Report 2026
Download Free Sample Buy Now
Neurological Disorder Drugs Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Neurological Disorder Drugs Market Report 2026

Global Outlook – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes), By Indication (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Neurological Disorder Drugs Market Overview

• Neurological Disorder Drugs market size has reached to $89.24 billion in 2025

• Expected to grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%

• Growth Driver: Rising Neurological Disorders Drive Growth In Drugs Market

• Market Trend: Advancements In Ocrelizumab Drug Delivery Technologies Enhance Treatment Accessibility And Clinical Outcomes In Multiple Sclerosis

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neurological Disorder Drugs Market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

The main types of drug classes in neurological disorders are cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonists, antiepileptics, antipsychotics, antidepressants, and others. Cholinesterase inhibitors are medications that prevent the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. Which can be used for various indications such as epilepsy, alzheimer’s disease, parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others, through various routes of administration, including oral, parenteral, and others. And these can be distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others, and end users are hospitals, specialty clinics, home care, and others.

Neurological Disorder Drugs Market Global Report 2026 Market Report bar graph

What Is The Neurological Disorder Drugs Market Size and Share 2026?

The neurological disorder drugs market size has grown strongly in recent years. It will grow from $89.24 billion in 2025 to $94.49 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising prevalence of epilepsy and neurodegenerative diseases, aging global population, long-term use of symptomatic neurological drugs, expansion of hospital-based neurological care, increased diagnosis rates of neurological disorders.

What Is The Neurological Disorder Drugs Market Growth Forecast?

The neurological disorder drugs market size is expected to see strong growth in the next few years. It will grow to $116.27 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to advancements in neurological drug development pipelines, growing burden of alzheimer’s and parkinson’s disease, increasing access to neurological care in emerging markets, rising demand for personalized neurology treatments, expansion of homecare and outpatient neurological therapy. Major trends in the forecast period include growing adoption of disease-modifying neurological therapies, rising focus on early diagnosis and long-term disease management, increased demand for combination drug therapies, expansion of oral and home-based neurological treatments, higher emphasis on symptom management and quality of life improvement.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Neurological Disorder Drugs Market Segmentation

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Is The Driver Of The Neurological Disorder Drugs Market?

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological disorder drugs market going forward. Neurological disorders refer to the conditions affecting the brain, spinal cord, and nerves caused by structural, biochemical, or electrical abnormalities, leading to various symptoms. The increase in neurological diseases is attributed to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. Neurological disorder drugs play a critical role in managing these complex conditions, offering relief from symptoms, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Therefore, the increasing prevalence of neurological disease is driving the growth of the neurological disorder drugs industry.

Key Players In The Global Neurological Disorder Drugs Market

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Global Neurological Disorder Drugs Market Trends and Insights

Major companies operating in the neurological disorder drugs market are focusing on developing innovative solutions such as Ocrelizumab-based therapies to enhance treatment efficacy, improve patient outcomes, and expand therapeutic options for individuals with multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody designed to target CD20-positive B cells, helping reduce disease activity and slow progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq), a twice-yearly, approximately 10-minute subcutaneous injection, marking the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This enhanced delivery option is designed to improve convenience, expand access to therapy, and support clinical workflow efficiency by offering a faster, non-intravenous method of administration.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Neurological Disorder Drugs Market?

In March 2024, Bristol-Myers Squibb Company (BMS), a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. Through this acquisition, BMS aims to strengthen its global neuroscience portfolio by gaining Karuna’s lead asset KarXT (xanomeline–trospium), a first-in-class muscarinic receptor modulator in development for neurological and psychiatric indications such as schizophrenia and Alzheimer’s disease–related psychosis. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company specializing in novel therapies for neurological and neuropsychiatric conditions.

Regional Insights

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neurological Disorder Drugs Market?

The neurological disorder drugs market consists of sales of antiepileptic drugs, dopaminergic agents, cholinesterase inhibitors, immunomodulatory drugs, and antipsychotic drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurological Disorder Drugs Market Report 2026?

The neurological disorder drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurological disorder drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Neurological Disorder Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $94.49 billion
Revenue Forecast In 2035 $116.27 billion
Growth Rate CAGR of 5.9% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Class, Indication, Route Of Administration, Distribution Channel, End-Users
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceu
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Neurological Disorder Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Neurological Disorder Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Neurological Disorder Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Neurological Disorder Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Growing Adoption Of Disease-Modifying Neurological Therapies

4.2.2 Rising Focus On Early Diagnosis And Long-Term Disease Management

4.2.3 Increased Demand For Combination Drug Therapies

4.2.4 Expansion Of Oral And Home-Based Neurological Treatments

4.2.5 Higher Emphasis On Symptom Management And Quality Of Life Improvement

5. Neurological Disorder Drugs Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Homecare Settings

5.4 Neurology Treatment Centers

5.5 Rehabilitation Centers

6. Neurological Disorder Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neurological Disorder Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Neurological Disorder Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Neurological Disorder Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Neurological Disorder Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Neurological Disorder Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neurological Disorder Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neurological Disorder Drugs Market Segmentation

9.1. Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

9.2. Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

9.3. Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Oral, Parenteral, Other Routes Of Administration

9.4. Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

9.5. Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Specialty Clinics, Homecare, Other End Users

9.6. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Donepezil, Rivastigmine, Galantamine

9.7. Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Memantine, Other NMDA Receptor Antagonists

9.8. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

9.9. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

9.10. Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

10. Neurological Disorder Drugs Market Regional And Country Analysis

10.1. Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neurological Disorder Drugs Market

11.1. Asia-Pacific Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neurological Disorder Drugs Market

12.1. China Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neurological Disorder Drugs Market

13.1. India Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neurological Disorder Drugs Market

14.1. Japan Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neurological Disorder Drugs Market

15.1. Australia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neurological Disorder Drugs Market

16.1. Indonesia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neurological Disorder Drugs Market

17.1. South Korea Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neurological Disorder Drugs Market

18.1. Taiwan Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neurological Disorder Drugs Market

19.1. South East Asia Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neurological Disorder Drugs Market

20.1. Western Europe Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neurological Disorder Drugs Market

21.1. UK Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neurological Disorder Drugs Market

22.1. Germany Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neurological Disorder Drugs Market

23.1. France Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neurological Disorder Drugs Market

24.1. Italy Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neurological Disorder Drugs Market

25.1. Spain Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neurological Disorder Drugs Market

26.1. Eastern Europe Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neurological Disorder Drugs Market

27.1. Russia Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neurological Disorder Drugs Market

28.1. North America Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neurological Disorder Drugs Market

29.1. USA Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neurological Disorder Drugs Market

30.1. Canada Neurological Disorder Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neurological Disorder Drugs Market

31.1. South America Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neurological Disorder Drugs Market

32.1. Brazil Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neurological Disorder Drugs Market

33.1. Middle East Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neurological Disorder Drugs Market

34.1. Africa Neurological Disorder Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Neurological Disorder Drugs Market, Segmentation By Drug Class, Segmentation By Indication, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neurological Disorder Drugs Market Regulatory and Investment Landscape

36. Neurological Disorder Drugs Market Competitive Landscape And Company Profiles

36.1. Neurological Disorder Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Neurological Disorder Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Neurological Disorder Drugs Market Company Profiles

36.3.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

37. Neurological Disorder Drugs Market Other Major And Innovative Companies

Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc

38. Global Neurological Disorder Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neurological Disorder Drugs Market

40. Neurological Disorder Drugs Market High Potential Countries, Segments and Strategies

40.1 Neurological Disorder Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Neurological Disorder Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Neurological Disorder Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Neurological Disorder Drugs Market, Overview Of Key Products - Product Examples
  • Table 2: Global Neurological Disorder Drugs Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Neurological Disorder Drugs Market, Supply Chain Analysis
  • Table 4: Global Neurological Disorder Drugs Market, Major Raw Material Providers
  • Table 5: Global Neurological Disorder Drugs Market, Major Resource Providers
  • Table 6: Global Neurological Disorder Drugs Market, Major Manufacturers (Suppliers)
  • Table 7: Global Neurological Disorder Drugs Market, Major Distributors And Channel Partners
  • Table 8: Global Neurological Disorder Drugs Market, Key Technologies & Future Trends
  • Table 9: Global Neurological Disorder Drugs Market, Major Trends
  • Table 10: Global Neurological Disorder Drugs Market, Major End Users
  • Table 11: Global Neurological Disorder Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Neurological Disorder Drugs Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Neurological Disorder Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Neurological Disorder Drugs Market - TAM, US$ Billion, 2025
  • Table 15: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: Taiwan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: Taiwan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: South East Asia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: South East Asia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 98: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 99: Global Neurological Disorder Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 100: Global Neurological Disorder Drugs Market - Company Scoring Matrix
  • Table 101: F. Hoffmann-La Roche Ltd Financial Performance
  • Table 102: Bayer AG Financial Performance
  • Table 103: Sanofi S.A Financial Performance
  • Table 104: AstraZeneca PLC Financial Performance
  • Table 105: Abbott Laboratories Financial Performance
  • Table 106: Global Neurological Disorder Drugs Market, Competitive Benchmarking (In USD Billions)
  • Table 107: Global Neurological Disorder Drugs Market, Competitive Dashboard
  • Table 108: Global Neurological Disorder Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 109: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 110: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Table 111: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

List Of Figures

    Figure 1: Global Neurological Disorder Drugs Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Neurological Disorder Drugs Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Neurological Disorder Drugs Market, Supply Chain Analysis
  • Figure 4: Global Neurological Disorder Drugs Market, Major Raw Material Providers
  • Figure 5: Global Neurological Disorder Drugs Market, Major Resource Providers
  • Figure 6: Global Neurological Disorder Drugs Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Neurological Disorder Drugs Market, Major Distributors And Channel Partners
  • Figure 8: Global Neurological Disorder Drugs Market, Key Technologies & Future Trends
  • Figure 9: Global Neurological Disorder Drugs Market, Major Trends
  • Figure 10: Global Neurological Disorder Drugs Market, Major End Users
  • Figure 11: Global Neurological Disorder Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Neurological Disorder Drugs Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Neurological Disorder Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Neurological Disorder Drugs Market - TAM, US$ Billion, 2025
  • Figure 15: Global Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Neurological Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Neurological Disorder Drugs Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Cholinesterase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Neurological Disorder Drugs Market, Sub-Segmentation Of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antiepileptic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Antipsychotic and Antidepressant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Neurological Disorder Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Global Neurological Disorder Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Global Neurological Disorder Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: Asia-Pacific, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: China, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: China, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: India, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: India, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Japan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Japan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Australia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Australia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: Indonesia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: Indonesia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: South Korea, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: South Korea, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: Taiwan, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: Taiwan, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: South East Asia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: South East Asia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: Western Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: Western Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: UK, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: UK, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: Germany, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: Germany, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: France, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: France, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Italy, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Italy, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Spain, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Spain, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Eastern Europe, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: Russia, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: Russia, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: North America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: North America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: USA, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: USA, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: Canada, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: Canada, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: South America, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: South America, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Brazil, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Brazil, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Middle East, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Middle East, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Neurological Disorder Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Africa, Neurological Disorder Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 98: Africa, Neurological Disorder Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 99: Global Neurological Disorder Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 100: Global Neurological Disorder Drugs Market - Company Scoring Matrix
  • Figure 101: F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 102: Bayer AG Financial Performance
  • Figure 103: Sanofi S.A Financial Performance
  • Figure 104: AstraZeneca PLC Financial Performance
  • Figure 105: Abbott Laboratories Financial Performance
  • Figure 106: Global Neurological Disorder Drugs Market, Competitive Benchmarking (In USD Billions)
  • Figure 107: Global Neurological Disorder Drugs Market, Competitive Dashboard
  • Figure 108: Global Neurological Disorder Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 109: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 110: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Indication, 2025 – 2030
  • Figure 111: Global, Neurological Disorder Drugs Market Size Gain ($ Billion), Segmentation By Route Of Administration, 2025 – 2030

Oral Transmucosal Drugs Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Oral Transmucosal Drugs Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Oral Transmucosal Drugs Market Landscape: Innovative Preservative-Free Lubricant Eye Drops For Rapid Relief And Lasting Hydration

Read More About Emerging Trends Redefining the Oral Transmucosal Drugs Market Landscape: Innovative Preservative-Free Lubricant Eye Drops For Rapid Relief And Lasting Hydration

Top Trends Driving Innovation and Change in the Over The Counter (OTC) Drugs Market: Advancements In Over-The-Counter Nasal Sprays Transforming The Over-The-Counter Drug Market

Read More About Top Trends Driving Innovation and Change in the Over The Counter (OTC) Drugs Market: Advancements In Over-The-Counter Nasal Sprays Transforming The Over-The-Counter Drug Market

Market Trends Influencing Strategic Decisions in the Oxycodone Drugs Industry: Focus On Developing Immediate-Release Tablets To Combat Drug Abuse In Oxycodone Drug Market

Read More About Market Trends Influencing Strategic Decisions in the Oxycodone Drugs Industry: Focus On Developing Immediate-Release Tablets To Combat Drug Abuse In Oxycodone Drug Market

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Read More About Discover key trends and market dynamics in the Smoking Cessation & Nicotine De-addiction Products Market with 2025 insights from The Business Research Company.

Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route O...

Cholinergic Drugs Market Report 2026 - Global Outlook – By Type (Powder, Tablet, Capsule), By Drug Type (Muscarinic Agonists, Nicotinic Agonists, Acetylcholinesterase Inhibitors), By Indication (Alzheimer's Disease, Myas...

Rare Neurological Disease Treatment Market Report 2026 - Global Outlook – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Disease-Modifying Neurological T...

Alzheimer's Drugs Market Report 2026 - Global Outlook – By Drugs (Donepezil, Rivastigmine, Galantamine, Memantine ), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy ), By Application (Early T...

Generic Central Nervous System Drugs Market Report 2026 - Global Outlook – By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types),...

Epilepsy Drugs Market Report 2026 - Global Outlook – By Seizure Type (Focal Seizures, Generalized Seizures), By Generation Type (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-...

Antipsychotic Drugs Market Report 2026 - Global Outlook – By Therapeutic Class (First Generation, Second Generation, Third Generation), By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Other Di...

Neurological Disorder Drugs Market Report 2026 - Global Outlook – By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs C...

Frequently Asked Questions

The Neurological Disorder Drugs Market Report 2026 market was valued at $89.24 billion in 2025, increased to $94.49 billion in 2026, and is projected to reach $116.27 billion by 2030. request a sample here

The expected CAGR for the Neurological Disorder Drugs Market Report 2026 market during the forecast period 2025–2030 is 5.3%. request a sample here

Major growth driver of the market includes: Rising Neurological Disorders Drive Growth In Drugs Market in the Neurological Disorder Drugs Market Report 2026 market. For further insights on this market, request a sample here

The neurological disorder drugs market covered in this report is segmented –
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users Subsegments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications request a sample here

Major trend in this market includes: Advancements In Ocrelizumab Drug Delivery Technologies Enhance Treatment Accessibility And Clinical Outcomes In Multiple Sclerosis For further insights on this market, request a sample here.

Major companies operating in the Neurological Disorder Drugs Market Report 2026 market are Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Nov request a sample here.

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us